KAP for Treatment-Resistant Depression: A Structured Clinical Approach
For patients who have spent years cycling through antidepressants — each trial bringing hope and then disappointment — the term "treatment-resistant depression" can feel like a verdict. It is not. It is a clinical designation that opens the door to a different category of treatment, one that works through an entirely different biological pathway. Ketamine-Assisted Psychotherapy (KAP) has emerged as one of the most evidence-supported options for this population, and understanding what it actually involves — mechanistically, clinically, and practically — is essential before considering it as a path forward.
What Treatment-Resistant Depression Actually Means
Treatment-resistant depression (TRD) has a precise clinical definition: a major depressive episode that has not responded adequately to at least two antidepressant trials of sufficient dose and duration — typically six to eight weeks at a therapeutic dose. By this definition, TRD is not a rare edge case. Estimates suggest that approximately one-third of patients with major depression meet criteria for TRD after multiple treatment attempts. For these individuals, continuing to rotate through SSRIs, SNRIs, and augmentation strategies often yields diminishing returns. TRD represents a genuine clinical impasse, not a failure of effort or willingness on the patient's part.
Why Ketamine Works Differently: The Glutamate Mechanism
Every conventional antidepressant — from fluoxetine to venlafaxine to mirtazapine — acts primarily on the monoamine system, targeting serotonin, norepinephrine, or dopamine. Ketamine operates through a completely different mechanism. It is an NMDA (N-methyl-D-aspartate) receptor antagonist, meaning it modulates glutamate, the brain's primary excitatory neurotransmitter.
Current neurobiological models suggest that in depression, glutamatergic signaling becomes dysregulated, impairing synaptic plasticity — the brain's ability to form and strengthen neural connections. Ketamine appears to rapidly restore this plasticity by triggering a surge in BDNF (brain-derived neurotrophic factor) and activating AMPA receptors. The result is rapid synaptogenesis: the growth of new synaptic connections in prefrontal circuits involved in mood regulation. This is a fundamentally different biological target than anything conventional antidepressants address, which is precisely why ketamine can work when other treatments have not.
Speed of Effect: Hours, Not Weeks
One of the most clinically significant features of ketamine is its onset of action. While SSRIs typically require two to six weeks to produce meaningful antidepressant effects, ketamine can produce measurable reductions in depressive symptoms within hours to days of a single administration. This rapid effect has been documented consistently across clinical trials and is especially relevant for patients with severe depression, significant functional impairment, or passive suicidal ideation — situations where waiting weeks for a medication to work carries real clinical risk. It is important to set realistic expectations: rapid does not mean permanent, and a single session is rarely sufficient for sustained benefit.
Why KAP Is More Than Just Ketamine
Ketamine alone — administered without any structured psychotherapeutic framework — can produce transient antidepressant effects. KAP, by contrast, integrates ketamine administration with intentional psychotherapy to extend, deepen, and consolidate those effects. The reasoning is both neurobiological and psychological.
During and immediately following a ketamine session, the brain enters a state of heightened neuroplasticity — sometimes described as a window of increased psychological flexibility. This window is therapeutically valuable. When paired with skilled psychotherapy, patients have an opportunity to process entrenched patterns, access emotions that are normally defended against, and integrate insights that may not surface in ordinary states of consciousness. The therapy component is not supplementary; evidence increasingly suggests it is central to durable outcomes. Without integration work, the biological window closes and old patterns reassert themselves.
What a Realistic Treatment Course Looks Like
A structured KAP course typically involves the following phases:
- Psychiatric evaluation: A thorough assessment to confirm the diagnosis, review prior treatment history, screen for contraindications, and establish baseline functioning. This is not a formality — it is the clinical foundation for safe and appropriate treatment.
- Preparation sessions: One to two psychotherapy sessions conducted before any ketamine administration. These sessions establish therapeutic rapport, set intentions, address concerns, and help the patient approach the experience with psychological readiness.
- Ketamine sessions: Typically a series of six sessions over two to three weeks for an initial course, administered by a physician in a monitored clinical setting. Sessions last approximately 60 to 90 minutes, during which the patient remains with a therapist in a supported, non-directive environment.
- Integration sessions: Psychotherapy sessions following each ketamine administration to process the experience, identify meaningful material, and translate psychological insights into behavioral and relational changes.
- Maintenance planning: Depending on response, some patients benefit from periodic booster sessions or continuation of conventional antidepressants alongside KAP. There is no universal protocol; maintenance is individualized.
The Evidence Base
The evidence for ketamine in TRD is substantial and growing. Intravenous racemic ketamine has been studied for over two decades, with multiple randomized controlled trials demonstrating significant antidepressant efficacy compared to placebo. The FDA approval of esketamine (Spravato) in 2019 for TRD provided regulatory validation of the mechanism. The literature on KAP as an integrated model — combining ketamine with structured psychotherapy — is more recent but accumulating, with clinical outcomes data supporting improved durability of response compared to ketamine alone.
Who May Be a Candidate
KAP may be appropriate for adults who meet the following general criteria:
- A diagnosis of major depressive disorder with an inadequate response to at least two antidepressant trials
- Absence of active psychotic symptoms or a personal or family history of primary psychotic disorders
- No history of ketamine or dissociative drug misuse
- Medically stable cardiovascular status, as ketamine transiently raises blood pressure and heart rate
- Motivation to engage meaningfully in both the preparation and integration components of therapy
Important Caveats
KAP is not a cure, and it is not appropriate for every patient with depression. The dissociative effects of ketamine are meaningful and require careful clinical framing — patients should not enter treatment without a clear understanding of what the experience involves. Ketamine carries a risk of psychological dependence in vulnerable individuals, which is one reason structured clinical oversight is non-negotiable. For patients with a history of substance use disorders, careful risk-benefit analysis is required rather than blanket exclusion. Additionally, while antidepressant effects can be rapid, they are not always durable without ongoing support. KAP is most appropriately understood as a catalyst — one that may meaningfully shift the trajectory of a depression that has not responded to other treatments, but which works best within a broader framework of psychiatric and psychotherapeutic care.
For patients who have been living with TRD, the honest message is this: a different mechanism exists, the evidence supports its use, and structured clinical implementation significantly improves outcomes. That is not a promise — it is a clinically grounded basis for cautious, informed hope.
Adapted from the clinical practice of Dr. Andrew Dror Rosenbach, MD.
